Introduction
Studies
evaluating the cost-effectiveness of screening for Hepatitis B Virus (HBV) and
Hepatitis C Virus (HCV) are generally heterogeneous in terms of risk groups,
settings, screening intervention, outcomes and the economic modelling
framework. It is therefore difficult to compare cost-effectiveness results
between studies. This systematic review aims to summarise and critically assess
existing economic models for HBV and HCV in order to identify the main
methodological differences in modelling approaches.
Methods
A
structured search strategy was developed and a systematic review carried out. A
critical assessment of the decision-analytic models was carried out according
to the guidelines and framework developed for assessment of decision-analytic
models in Health Technology Assessment of health care interventions.
Results
The
overall approach to analysing the cost-effectiveness of screening strategies
was found to be broadly consistent for HBV and HCV. However, modelling
parameters and related structure differed between models, producing different
results. More recent publications performed better against a performance
matrix, evaluating model components and methodology.
Conclusion
When assessing screening strategies for HBV and HCV
infection, the focus should be on more recent studies, which applied the latest
treatment regimes, test methods and had better and more complete data on which
to base their models. In addition to parameter selection and associated
assumptions, careful consideration of dynamic versus static modelling is
recommended. Future research may want to focus on these methodological issues.
In addition, the ability to evaluate screening strategies for multiple
infectious diseases, (HCV and HIV at the same time) might prove important for
decision makers.
Below: Summary of Cost-Effectiveness Results, HBV
Full article at: http://goo.gl/cPJXwD
By:
Claudia Geue, Olivia Wu, Yiqiao Xin, Robert Heggie
Health Economics and Health Technology Assessment, Institute
of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
Sharon Hutchinson
School of Health and Life Sciences, Glasgow Caledonian University,
Glasgow, United Kingdom
Natasha K. Martin
Division of Global Public Health, University of California
San Diego, San Diego, California, United States of America
Natasha K. Martin
School of Social and Community Medicine, University of
Bristol, Bristol, United Kingdom
Elisabeth Fenwick
ICON Health Economics and Epidemiology, Dublin, Ireland
David Goldberg
Health Protection Scotland, NHS Health Scotland, Glasgow,
United Kingdom
More at: https://twitter.com/hiv_insight
No comments:
Post a Comment